Ozempic / GLP-1 Lawsuit Calculator
MDL 3094 (E.D. Pa.) gastroparesis + separate NAION MDL. Semaglutide/Wegovy/Mounjaro/Zepbound/Rybelsus. 4,022 + 216 cases (Sept 1, 2026). Pre-bellwether phase — no trial dates set
Are there any settlements yet? No — this is pre-bellwether litigation, and no court has set or approved any payout amount. Dollar ranges circulating online are law-firm projections, not court figures; the vision-loss (NAION) cases are in a separate MDL 3163 that has not reached its causation rulings.
⚖ MDL 3094 (E.D. Pa.) gastroparesis — 4,022 cases. NAION MDL 3163 — 216 cases (Sept 1, 2026). Rule 702 hearing held Sept 14–18, 2026 (MDL 3094). No trial dates set.
Your Case Details
Answer a few questions to see your estimated range.
Higher-tier injuries qualify for higher settlement tiers.
Estimated Settlement Tier
$105,000 — $195,000
Mass tort settlements use injury-severity tiers. Most MDLs have published payment matrices — your tier depends on diagnosis + exposure proof.
Revisado Editorialmente — Contenido revisado en cuanto a exactitud utilizando investigación legal publicada, datos gubernamentales y registros judiciales verificados. Vea nuestra metodología
Reviewed by Leonard Goldberg, Editor · Last updated
Ozempic / GLP-1 MDL — Early Stage
GLP-1 receptor agonists: Ozempic/semaglutide (Novo Nordisk), Wegovy (Novo), Mounjaro/tirzepatide (Eli Lilly), Zepbound (Lilly), Rybelsus (Novo). Allegedly cause: (1) severe gastroparesis (stomach paralysis), ileus, intestinal obstruction, aspiration during anesthesia; (2) NAION (non-arteritic anterior ischemic optic neuropathy — sudden vision loss).
Two MDLs: (1) MDL 3094 (E.D. Pa., Judge Karen S. Marston) — gastrointestinal injuries, 4,022 lawsuits (JPML census, September 1, 2026). (2) MDL 3163 (separate docket, E.D. Pa., same judge) — NAION vision loss, 216 lawsuits as of the September 1, 2026 JPML census, up from 110 on June 1. Its expert and summary-judgment motions are due July 2, 2027. Details: our NAION tracker. Related gastrointestinal cases also proceed in New Jersey state court and are not included in these counts.
Status: EARLY ACTIVE — pre-bellwether. No global settlement. No bellwether trials scheduled. MDL 3094: the Rule 702 (Daubert) hearing on warnings/preemption + general causation was held September 14–18, 2026 — ruling pending (none posted as of September 27, 2026). MDL 3163 (NAION): expert reports due March 26, 2027; Rule 702 + summary-judgment motions due July 2, 2027. Defendants deny causation + contest warning adequacy. These are blockbuster drugs with massive economic interests — Novo + Lilly have significant defense resources.
Who May Qualify for an Ozempic Lawsuit?
You may have a claim if ALL apply:
- You took Ozempic, Wegovy, Mounjaro, or Zepbound (GLP-1 / GIP drugs)
- You were diagnosed with gastroparesis (stomach paralysis), severe intestinal blockage, NAION vision loss, or gallbladder disease
- Your diagnosis came after starting the medication (typically used for ≥several months)
- You have medical records documenting both the prescription and the injury
The MDL (multidistrict litigation) is consolidating cases — no settlement exists yet, so filing now preserves your place. Statute of limitations varies by state (often 2-3 years from diagnosis).
The Two Main Injury Tracks
Ozempic litigation splits into distinct injury categories. Which track you're in affects case strength and potential value. The gastrointestinal track is MDL 3094; since December 2025 the NAION vision-loss track has its own MDL 3163 — both in the Eastern District of Pennsylvania.
Gastrointestinal Track (Gastroparesis / Stomach Paralysis)
The largest group. Plaintiffs allege GLP-1 drugs caused gastroparesis (stomach paralysis), severe vomiting, intestinal obstruction, or ileus. In January 2025, the Ozempic label was updated to state it is "not recommended in patients with severe gastroparesis" — though it does not admit the drug causes the condition.
NAION Vision Loss Track
A newer, separate group. Plaintiffs allege semaglutide caused NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) — sudden, often permanent vision loss. A 2024 Harvard study linked semaglutide to elevated NAION risk, fueling these claims.
Estimated Case Values — IMPORTANT: No Settlement Exists Yet
There is NO global Ozempic settlement as of 2026. No money has been awarded. The figures below are attorney projections based on similar pharmaceutical MDLs — NOT guaranteed amounts. Actual values depend on bellwether trial outcomes (no trial dates set yet) and individual case facts. Anyone promising you a specific dollar amount now is misleading you.
| Severity | Tier | Estimate (NOT guaranteed) |
|---|---|---|
| Severe (hospitalization, surgery, permanent gastroparesis) | Higher-tier projection | $400,000–$700,000+ (estimate) |
| Moderate (ongoing treatment, documented diagnosis) | Mid-tier projection | $100,000–$400,000 (estimate) |
| Mild / unconfirmed causation | Lower-tier or no recovery | $0–$100,000 (estimate) |
Current MDL Status (September 2026)
The Ozempic litigation is in active pre-trial phase. No settlement, no payouts yet. Here's exactly where it stands:
Last verified: September 27, 2026. Litigation status changes frequently — verify current MDL status before relying on any figure. This page is informational, not legal advice.
Ozempic MDL Timeline
- 1
2023: First Lawsuits Filed
Plaintiffs begin filing claims alleging Novo Nordisk (Ozempic/Wegovy) and Eli Lilly (Mounjaro/Zepbound) failed to warn about gastroparesis and severe GI risks.
- 2
February 2024: MDL 3094 Created
The Judicial Panel on Multidistrict Litigation consolidates federal cases into MDL 3094 in the Eastern District of Pennsylvania before Judge Karen S. Marston.
- 3
January 2025: Label Update
Ozempic's label is updated to state it is "not recommended in patients with severe gastroparesis" — a development plaintiffs cite, though it stops short of admitting causation.
- 4
2025-2026: Discovery + Case Growth
MDL grows to 4,022 lawsuits (September 1, 2026). Discovery and expert work focus on the cross-cutting issues (gastroparesis diagnosis, warnings/preemption, general causation). NAION vision-loss claims get their own MDL 3163 (December 2025).
- 5
September 14–18, 2026: Rule 702 Hearing (MDL 3094)
Five-day evidentiary hearing on expert testimony for cross-cutting issues 2 and 3 (warnings/preemption and general causation), moved from September 10–18. The ruling will shape whether and how the gastrointestinal cases move toward bellwether (test) trials; no trial dates are set.
Realistic Case Scenarios
Hypothetical examples illustrating how case strength varies. These are NOT settlement offers — no settlement exists. Values are attorney projections for similar MDLs:
Hospitalized Gastroparesis, Surgery Required
Patient took Ozempic 14 months for weight loss, developed severe gastroparesis requiring hospitalization and a gastric procedure. Full medical records + prescription history.
Higher-tier projection ($400K-$700K+ estimate) — strong causation + documented severe injury. Only realized IF the MDL settles or a jury awards damages.
Check if this is your situation →Moderate Gastroparesis, Ongoing Treatment
Patient took Wegovy 8 months, diagnosed with gastroparesis, managed with medication and diet. Clear diagnosis, no surgery.
Mid-tier projection ($100K-$400K estimate) — solid claim, value depends on bellwether outcomes.
Check if this is your situation →NAION Vision Loss
Patient on semaglutide developed sudden vision loss diagnosed as NAION. Ophthalmology records link timing to the drug.
Separate NAION track — newer litigation, value highly uncertain pending the science and early trials.
Check if this is your situation →Mild Symptoms, No Formal Diagnosis
Patient experienced nausea and vomiting on Ozempic but no formal gastroparesis diagnosis or hospitalization.
Weak claim ($0-$100K estimate or no recovery) — without a documented qualifying diagnosis, causation is hard to prove.
Check if this is your situation →Took Drug, No Injury
Patient used Ozempic for diabetes with no adverse GI or vision event.
$0 — no injury, no claim. The lawsuit requires a documented qualifying injury.
Check if this is your situation →Ozempic Lawsuit Scams — Red Flags
Active mass torts with no settlement yet are scam magnets. Watch for these:
1. "Guaranteed $X Ozempic Settlement Payout"
There is NO settlement. Anyone guaranteeing a specific payout is lying. Real attorneys give ranges with heavy caveats and explain that bellwether trials (not yet scheduled) determine everything.
2. "Pay an Upfront Fee to Join the Lawsuit"
Legitimate mass-tort attorneys work on contingency — they only get paid if you recover. Never pay upfront to "join" or "register" for the Ozempic MDL.
3. Pressure to "Sign Today or Lose Your Claim"
While statutes of limitations are real, high-pressure "sign now" tactics are a red flag. A reputable firm explains your specific deadline based on your state and diagnosis date.
4. Requests for SSN, Bank, or Card Info to "Process Your Claim"
Case intake needs medical records and prescription history — not your bank account or card numbers. Anyone demanding financial credentials to "process" a non-existent settlement is a scammer.
5. Fake "Ozempic Settlement Administrator" Sites
Since no settlement exists, there is NO official settlement administrator yet. Sites claiming to be "the official Ozempic settlement" with claim forms are fraudulent. Verify any law firm independently.
Ozempic / GLP-1 FAQs
Can I file even if I took Ozempic for diabetes (not weight loss)?
Yes — both diabetes and weight-loss patients are in scope. Both indications use the same active ingredient + same alleged side effects. Your FDA-approved use case doesn't matter for tort liability.
Is Mounjaro (Lilly) in the same lawsuit?
Yes — MDL 3094 covers Lilly's GLP-1 drugs (Mounjaro/tirzepatide, Zepbound) as well as Novo Nordisk's (Ozempic, Wegovy, Rybelsus). Defendants are both manufacturers, plus distributors.
How long will this litigation take?
No trial dates have been set in either MDL — the court is deciding cross-cutting expert and preemption questions first (MDL 3094 hearing held September 14–18, 2026; NAION motions due July 2, 2027). Global settlement unlikely before 2028+. Statutes of limitations keep running while the MDL proceeds and vary by state; expect a multi-year wait. Daubert challenges may end or narrow litigation — though in the Tylenol MDL, the appeals court held in July 2026 that three of the plaintiffs' experts had been wrongly excluded (it upheld two other exclusions) and vacated the judgments against the plaintiffs.
Does 'stomach paralysis' mean I qualify?
Yes, if you have a documented gastroparesis diagnosis linked to GLP-1 use. Standard label side effects (nausea, vomiting) alone likely don't qualify. Clinical gastroparesis diagnosis typically required via gastric emptying study + GI specialist.
I stopped taking the drug + symptoms resolved — do I still qualify?
Possible — document the diagnosis + hospitalization regardless of current status. Even resolved cases may qualify for compensation if medical treatment + hospitalization occurred during active symptoms.
Is the NAION (vision loss) claim strong?
A July 2024 JAMA Ophthalmology study (Mass Eye and Ear) reported an association between semaglutide + NAION, and in June 2025 the EMA's safety committee (PRAC) concluded that NAION is a very rare side effect of semaglutide. Causation is still being litigated. NAION has its own docket, MDL 3163, with 216 cases as of the September 1, 2026 JPML census, up from 110 on June 1. The court is deciding general causation first: plaintiffs' expert reports are due March 26, 2027, and Rule 702 motions July 2, 2027. Full status: our NAION tracker. If you experienced sudden, painless vision loss in one eye after starting Ozempic/similar, document immediately.
What if I only had nausea/vomiting, not gastroparesis?
Standard label side effects likely DON'T qualify. Clinical gastroparesis diagnosis is typically required — confirmed via gastric emptying study (4-hour nuclear medicine scan) + GI specialist evaluation. Without clinical diagnosis, claim is weak.
Is there a lawsuit against Ozempic — and are there any settlements yet?
Yes - the lawsuit against Ozempic and similar GLP-1 drugs is very real: claims against Novo Nordisk (and Eli Lilly for Mounjaro/Zepbound) are consolidated in MDL 3094 in the Eastern District of Pennsylvania. No — this is pre-bellwether litigation, and no court has set or approved any payout amount. Dollar ranges circulating online are law-firm projections, not court figures; the vision-loss (NAION) cases are in a separate MDL 3163 that has not reached its causation rulings.